Skip to content

Finished goods at other companies

Embecta Corp. logo
Embecta Corp.EMBC
$126.8M+7.5%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$4.6M
UFP Technologies logo
UFP TechnologiesUFPT
$15.23M
ICU Medical logo
ICU MedicalICUI
$289.36M+9.9%
Baxter International logo
Baxter InternationalBAX
AptarGroup logo
AptarGroupATR

Other financials

Income statement

See full
Revenue$11.8M+22.1%
Gross profit$7.2M+19.6%
Operating income-$864.9K+30.5%
Net income-$807.1K+30.8%
EPS (diluted)-$0.02+33.3%

Balance sheet

See full
Cash & equivalents$8.8M+0.4%
Total debt$3.5M-2.8%
Total equity$16.9M+3.5%
Total assets$28.6M+5.1%

Cash flow

See full
Operating cash flow$14.7K+106%
CapEx$46.2K-89.6%
Free cash flow-$31.5K+95.4%

Valuation

See full
Market cap$206.24M+24.9%
Enterprise value$200.96M+25.1%
P/S4.8×+0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin-6%-2.3pp
Net margin-5.3%-2.1pp
FCF margin-37.1%+23.7pp

Returns & leverage

See full
Return on equity-13.7%-4.8pp
Debt / equity0.2×0.0×
Current ratio2.3×-0.1×

Where this comes from

Reported directly by KORU Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoods.

The official record: KORU Medical Systems’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KORU Medical Systems's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KORU Medical Systems's finished goods?
KORU Medical Systems (KRMD) reported finished goods of $2.95M in Q4 2025.
How has KORU Medical Systems's finished goods changed year-over-year?
KORU Medical Systems's finished goods increased by 49.0% year-over-year, from $1.98M to $2.95M.
What is the long-term trend for KORU Medical Systems's finished goods?
Over 5 years (2020 to 2025), KORU Medical Systems's finished goods has grown at a -8.4% compound annual growth rate (CAGR), from $4.56M to $2.95M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.